Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2022-02-02 Regulatory Filings
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
New European patent approval for Episurf Medical
Regulatory Filings Classification · 1% confidence The document announces a specific, non-financial corporate event: the approval of a new European patent for Episurf Medical. It is a brief press release format, not a comprehensive report (like 10-K or IR). It does not fit the definitions for AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, DEF 14A, RPA, SHA, or POS. Since it is a specific regulatory announcement concerning intellectual property that doesn't fit the other specific categories, the most appropriate fallback is the general Regulatory Filings category (RNS). The document length is short (1793 chars), but it is the primary content, not an announcement *of* another report.
2022-02-02 English
Nytt europeiskt patentbeviljande för Episurf Medical
Regulatory Filings Classification · 1% confidence The document is a short announcement in Swedish regarding the granting of a new European patent for Episurf Medical. It details the patent subject ('Implant specific drill tool') and includes a quote from the COO. The final paragraph explicitly states that the information is required to be made public under the EU Market Abuse Regulation (MAR) and was released at a specific time. This type of announcement, concerning intellectual property (IP) protection, does not fit neatly into the primary financial reporting categories (10-K, IR, ER, etc.). Since it is a specific regulatory disclosure about an asset/legal matter (patent grant) that is not a standard financial report, the most appropriate classification is the general regulatory filing category, RNS (Regulatory Filings), as it serves as a catch-all for important, non-standard disclosures.
2022-02-02 Swedish
Förändring av antalet aktier och röster i Episurf Medical
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement in Swedish titled "Förändring av antalet aktier och röster i Episurf Medical" (Change in the number of shares and votes in Episurf Medical). It explicitly states that A-shares were converted to B-shares, resulting in a change in the total number of shares and votes. This directly relates to a change in the company's capital structure or share count. Based on the definitions, this fits best under 'Share Issue/Capital Change' (SHA), which covers changes in capital structure, or potentially 'Capital/Financing Update' (CAP). Since it is a direct notification of a change in the number of shares outstanding due to conversion, SHA is the most precise fit. The document is short and appears to be a direct regulatory disclosure, not an announcement of a larger report (ruling 2 does not apply).
2022-01-31 Swedish
Change in number of shares and votes in Episurf Medical
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly announces a 'Change in number of shares and votes in Episurf Medical' due to the conversion of class A-shares to B-shares. It details the exact change in the number of A-shares and B-shares, and the resulting total number of shares and votes. This directly relates to a change in the company's capital structure or share issuance details. Based on the definitions, 'Share Issue/Capital Change (Code: SHA)' is the most appropriate classification, as it covers changes in capital structure, which includes changes in the number of outstanding shares due to conversions. The document is short and appears to be a direct regulatory announcement, not a comprehensive report.
2022-01-31 English
Episurf’s implants approved for sale in Malaysia
Regulatory Filings Classification · 1% confidence The document announces that Episurf Medical's implant technologies have received approval from the Medical Device Authority (MDA) in Malaysia. This is a specific regulatory clearance announcement concerning a product's market access. This type of announcement, which details a specific regulatory event (approval/clearance) rather than a general financial result (ER, IR) or a management change (MANG), fits best under the general 'Regulatory Filings' category (RNS) as there is no more specific category for product regulatory approvals outside of the standard SEC forms (10-K, etc.). It is not an earnings release, an audit report, or a director's dealing. Given the nature of the announcement (regulatory clearance for a medical device), RNS is the most appropriate fallback.
2022-01-17 English
Episurfs implantat godkända för försäljning i Malaysia
Regulatory Filings Classification · 1% confidence The document is a short announcement in Swedish stating that Episurf Medical's implant technologies have received approval from the Malaysian authority MDA (Medical Device Authority). It details a regulatory milestone (product approval in a new market) and includes contact information and a boilerplate 'About Us' section. Crucially, the final paragraph states: "Denna information är sådan information som Episurf Medical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is such information that Episurf Medical AB is obliged to disclose according to the EU Market Abuse Regulation). This strongly suggests a mandatory regulatory disclosure. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific insider trade (DIRS), and it concerns a regulatory event (approval), it fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially a specific regulatory update if one existed. Given the options, RNS is the most appropriate fallback for a non-standard regulatory announcement that isn't explicitly covered by other codes like DIRS or DIV. The document length is very short (1800 chars), confirming it is an announcement, not the full report itself.
2022-01-17 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.